West Pharmaceutical Services Inc
NYSE:WST
Intrinsic Value
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. [ Read More ]
The intrinsic value of one
WST
stock under the Base Case scenario is
235.51
USD.
Compared to the current market price of 368.18 USD,
West Pharmaceutical Services Inc
is
Overvalued by 36%.
West Pharmaceutical Services Inc's market capitalization is 27.1B USD.
WST stock price is 368.18 USD.
WST stock (235.51 USD) is 36% less than its price (368.18 USD).
WST stock (341.43 USD) is 7% less than its price (368.18 USD). Open Relative Valuation
WST has upside potential of 11% compared to the average analyst price target.
Open Wall St Estimates
WST's ROIC (Return on Invested Capital) has increased in the last 3 years from 22% to 22%.
WST's Revenue has grown by 2% over the past 12 months.
WST's ROE (Return on Equity) has decreased in the last 3 years from 25% to 21%.
WST's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
WST's ROE (Return on Equity) for the past 12 months is positive and is equal to 21%.
WST's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 22%.
WST's Revenue has been growing by 11% per year for the last 3 years.
WST has positive Net Income for the last twelve months.
WST has positive Operating Income for the last twelve months.
WST has positive Free Cash Flow for the last twelve months.
WST has positive Gross Profit for the last twelve months.
WST has positive three-year average ROIC (Return on Invested Capital): 25%. The company is efficient at using invested capital to generate operating income.
WST has very high three-year average ROE (Return on Equity): 26%. The company is very efficient at transforming stockholders' equity into net income.
WST's short-term assets (2B USD) exceed its short-term liabilties (672m USD).
WST's D/E (Debt to Equity) is very low and is equal to 0.03.
WST's long-term assets (4B USD) exceed its long-term liabilties (949m USD).
WST has negative Net Debt. This means that the company has more cash and short-term investments (854m USD) than debt (73m USD).
WST's Altman Z-Score is very high and is equal to 19.17.
WST earns more than enough operating income (705m USD) to safely cover interest payments on its debt (6m USD).
Valuation Backtest
West Pharmaceutical Services Inc
Run backtest to discover the historical profit from buying and selling
WST
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
West Pharmaceutical Services Inc
Balance Sheet Decomposition
West Pharmaceutical Services Inc
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 853.9m |
| Receivables | 512m |
| Other Current Assets | 570.5m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 210m |
| PP&E | 1.5B |
| Intangibles | 123.6m |
| Other Non-Current Assets | 47m |
| Current Liabilities | 671.8m |
| Accounts Payable | 242.4m |
| Accrued Liabilities | 123.6m |
| Other Current Liabilities | 305.8m |
| Non-Current Liabilities | 276.7m |
| Long-Term Debt | 72.8m |
| Other Non-Current Liabilities | 203.9m |
Earnings Waterfall
West Pharmaceutical Services Inc
|
Revenue
|
2.9B
USD
|
|
Cost of Revenue
|
-1.8B
USD
|
|
Gross Profit
|
1.1B
USD
|
|
Operating Expenses
|
-424.1m
USD
|
|
Operating Income
|
705.1m
USD
|
|
Other Expenses
|
-111.7m
USD
|
|
Net Income
|
593.4m
USD
|
Free Cash Flow Analysis
West Pharmaceutical Services Inc
WST Profitability Score
Profitability Due Diligence
West Pharmaceutical Services Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
West Pharmaceutical Services Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
WST Solvency Score
Solvency Due Diligence
West Pharmaceutical Services Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
West Pharmaceutical Services Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WST Price Targets Summary
West Pharmaceutical Services Inc
According to Wall Street analysts, the average 1-year price target for
WST
is 408.44 USD
with a low forecast of 358.55 USD and a high forecast of 493.5 USD.
Ownership
WST Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
WST Price
West Pharmaceutical Services Inc
| Average Annual Return | 30.23% |
| Standard Deviation of Annual Returns | 58.26% |
| Max Drawdown | -56% |
| Market Capitalization | 27.1B USD |
| Shares Outstanding | 73 205 400 |
| Percentage of Shares Shorted | 2.02% |
Company Profile
West Pharmaceutical Services Inc
Country
Industry
Market Cap
Dividend Yield
Description
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,065 full-time employees. The firm operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Contact
IPO
Employees
Officers
The intrinsic value of one
WST
stock under the Base Case scenario is
235.51
USD.
Compared to the current market price of 368.18 USD,
West Pharmaceutical Services Inc
is
Overvalued by 36%.
You don't have any saved screeners yet
